@article{2e88bcdf9a2f4ed0b4b1f3d248ee6d04,
title = "Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease",
abstract = "Aim: To quantify characteristics in acute flaccid myelitis (AFM) at acute and convalescent stages. Method: This was a retrospective case series of children with AFM evaluated at a single institution in the USA (2014–2017). Acute inflammatory/ischemic myelopathies were excluded. Neurological assessments and segmental quantitative analysis of signal abnormalities on magnetic resonance imaging (MRI) of the brain and spinal cord were performed. Results: Sixteen patients (11 males, five females) were evaluated. Median age at onset was 4 years (interquartile range [IQR] 3–6y). All had parainfectious acute-onset limb weakness, lower motor neuron examination, and spinal fluid pleocytosis. On acute spinal cord MRI, longitudinally extensive T2 hyperintensities were identified throughout the spinal cord mostly within grey matter; five out of 12 patients had dorsal brainstem T2 hyperintensities. At a median of 2 months follow-up (IQR 2–3mo), spinal cord MRI improved in seven out of nine patients although focal T2 hyperintensities persisted in cervical and lumbar grey matter. At a median follow-up of 4 months (IQR 2–6mo), Medical Research Council sum score rose from a median of 29 to 32; distal muscle groups improved more than proximal ones; four out of 16 patients were ventilator-dependent; and two out of 16 patients were quadriplegic. Interpretation: While patients may show marked improvement on neuroimaging from acute to convalescent stages, the majority of children with AFM have limited motor recovery and continued disability. Clinicians should consider the timing of clinical and neuroimaging exams when assessing diagnosis and prognosis. What this paper adds: During the 2014 to 2017 acute flaccid myelitis outbreak in the USA, clinical recovery was better in distal than proximal muscle groups. Lumbar spinal cord showed more residual abnormalities at convalescence.",
author = "Eliza Gordon-Lipkin and Mu{\~n}oz, {Laura S.} and Klein, {Jessica L.} and Janet Dean and Izlem Izbudak and Pardo, {Carlos A.}",
note = "Funding Information: We are grateful with the individuals and their families who participated in this study through their generous contribution of their time and effort. We also acknowledge Dr Steven Salzberg for his support with molecular studies, and Drs Deanna Saylor and Michael Levy for their critical review. This research is supported by the Bart McLean Fund for Neuroimmunology Research, the Johns Hopkins Project Restore, and the Transverse Myelitis Association. Janet Dean currently serves in the Scientific Advisory Board of the Transverse Myelitis Association. Izlem Izbudak received research support from Siemens and Biogen, and serves as a consultant for Alexion Pharmaceuticals. Carlos A Pardo currently serves in the Scientific Advisory Board of the Transverse Myelitis Association and has received research support from the National Institutes of Health, Medimmune Oncology, Chugai Pharmaceuticals, and the Bart McLean Fund for Neuroimmunology Research, Johns Hopkins Project Restore. The authors have stated that they had no interests which could be perceived as posing a conflict or bias. Funding Information: We are grateful with the individuals and their families who participated in this study through their generous contribution of their time and effort. We also acknowledge Dr Steven Salzberg for his support with molecular studies, and Drs Deanna Saylor and Michael Levy for their critical review. This research is supported by the Bart McLean Fund for Neuroimmunology Research, the Johns Hopkins Project Restore, and the Transverse Myelitis Association. Janet Dean currently serves in the Scientific Advisory Board of the Transverse Myelitis Association. Izlem Izbudak received research support from Siemens and Biogen, and serves as a consultant for Alexion Pharmaceuticals. Carlos A Pardo currently serves in the Scientific Advisory Board of the Transverse Myelitis Association and has received research support from the National Institutes of Health, Medimmune Oncology, Chugai Pharmaceuticals, and the Bart McLean Fund for Neuroimmunol-ogy Research, Johns Hopkins Project Restore. The authors have stated that they had no interests which could be perceived as posing a conflict or bias. Publisher Copyright: {\textcopyright} 2018 Mac Keith Press",
year = "2019",
month = mar,
doi = "10.1111/dmcn.14030",
language = "English (US)",
volume = "61",
pages = "366--375",
journal = "Developmental Medicine and Child Neurology",
issn = "0012-1622",
publisher = "Wiley-Blackwell",
number = "3",
}